A row has broken out over proposals for a massive extension of the use of cholesterol-lowering statin drugs in England.
Nine senior doctors and academics have claimed the plans could damage the regulator of NHS watchdog, the National Institute for Health and Care Excellence.
NICE is considering cutting the threshold for prescription of statins to allow them to be prescribed to millions of people at quite a low risk of suffering heart disease or stroke.
They are currently prescribed when patients have a 20% risk of developing cardiovascular disease within ten years – but, according to the new proposals, this would be cut to 10%.
Royal College of Physicians president Sir Richard Thompson and former Royal College of GPs chair Dr Clare Gerada are among nine signatories of a letter to NICE criticising the proposals.
They allege that many members of the advisory committee drawing up the guidelines have pharmaceutical industry conflicts of interest.
And, according to the letter, the proposals would "medicalise five million healthy individuals."
The letter also cites the problem of "hidden data" held by pharmaceutical companies being shown to NICE but not being available to other experts to study.
Yesterday NICE defended its proposals.
Professor Mark Baker, of NICE, said: "The draft guideline does not propose that statins should be used instead of the lifestyle adjustments that people at risk of cardiovascular disease need to make – such as stopping smoking, being more active, drinking less alcohol, eating more healthily and losing weight.
"It encourages GPs to fully explore with their patients the ways in which people can reduce their risk of cardiovascular disease, presenting all the options promoted by the draft guidance, including lifestyle changes, blood pressure control, avoidance of diabetes and cholesterol (lipid) lowering, and to allow patients to make their own decisions.
"The independent committee of experts found that if a patient and their doctor measure the risk and decide statins are the right choice, the evidence clearly shows there is no credible argument against their safety and clinical effectiveness for use in people with a 10% risk over ten years.
"Because the price of statins has fallen, it is also cost-effective to use them to reduce the risk of cardiovascular disease at a lower threshold than NICE has previously recommended."
He added: "This guidance does not medicalise millions of healthy people. On the contrary, it will help prevent many from becoming ill and dying prematurely."

Leave a Reply